Randomized Study Comparing Accelerated and Standard Corneal Crosslinking Treatments for Progressive Keratoconus or Corneal Ectasia

What this Trial Is About

Researchers are comparing two methods of corneal crosslinking to treat progressive keratoconus or corneal ectasia, conditions that affect the shape and strength of the cornea. This study evaluates accelerated versus standard treatment to understand which approach better manages these eye conditions. The trial is conducted by the Price Vision Group and includes participants aged 10 years and older. Participants receive one of two treatments either 0.1% riboflavin eye drops with 9 mWcm2 UVA light for 10 minutes accelerated, or 0.1% riboflavin eye drops with 3 mWcm2 UVA light for 30 minutes standard. These treatments aim to strengthen the cornea using different light intensities and durations. The study randomly assigns participants to one of these two groups. During the study, researchers measure changes in the maximum keratometry, which assesses corneal curvature, at 6 months. They also track changes in both corrected and uncorrected distance visual acuity over the same period. Participants undergo eye examinations and monitoring to assess treatment effects and safety throughout the study.

Comparison of Standard vs. Accelerated Corneal Crosslinking